Bristol Myers Squibb’s Validation for Breakthrough Cancer Treatment
Bristol Myers Squibb’s immunotherapy combination therapy, Opdivo plus Yervoy, has received validation from the European Medicines Agency (EMA) for...
Parker Institute Pledges $125M for Cancer Cure Quest
The Parker Institute for Cancer Immunotherapy (PICI) has announced a significant $125 million investment to bolster its research and...
Data Unveils Susvimo’s Enduring Power in Treating Diabetic Eye Diseases
Susvimo, an innovative refillable eye implant, has shown promising results in Phase III clinical trials for treating DME and...
Leo Pharma Reveals Groundbreaking Phase 3 Success for Hand Eczema
LEO Pharma, a leader in dermatology, has announced the publication of its DELTA 1 and DELTA 2 phase 3...
Truvian Health Is Making Healthcare More Affordable and Accessible
Access to healthcare remains a challenge, with limited availability of routine blood testing globally. Truvian Health aims to solve...
NIH, FDA Effort Unveils Revolutionary Parkinson’s Diagnosis Advancements
A new partnership aims to improve diagnosis and outcomes for Parkinson’s disease and related disorders. The Accelerating Medicines Partnership...
Crescita Therapeutics Partners with NanoPass to Enhance Medical Aesthetics Portfolio
Crescita Therapeutics and NanoPass have entered an exclusive distribution agreement to introduce MicronJetTM600, an advanced intradermal delivery device, to...
Cota and Texas Oncology Team Up for Enhanced AI Precision Medicine
COTA, Inc. and Texas Oncology’s Precision Health Informatics (PHI) have forged a collaboration to transform precision medicine within Texas...
Bayer’s Nubeqa Triumph: A Milestone in Prostate Cancer Treatment
The Phase III ARANOTE trial has demonstrated significant benefits for NUBEQA (darolutamide) in combination with androgen deprivation therapy (ADT)...
Scorpion Therapeutics Secure $150M for Cancer-Fighting Pipeline
Scorpion Therapeutics, a leading oncology company, announced a successful $150 million Series C financing round to advance its precision...